Ixoberogene soroparvovec is a gene therapy commercialized by Adverum Biotechnologies, with a leading Phase II program in Wet (Neovascular / Exudative) Macular Degeneration. According to Globaldata, it is involved in 6 clinical trials, of which 2 were completed, 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Ixoberogene soroparvovec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Ixoberogene soroparvovec is expected to reach an annual total of $42 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ixoberogene soroparvovec Overview
ADVM-022 is under development for the treatment of wet age-related macular degeneration (wAMD, wet exudative macular degeneration). The drug candidate is a vector based anti-VEGF cDNA administered through intravitreal route. It acts by targeting vascular endothelial growth factor (VEGF). It is developed based on next generation adeno-associated virus (AAV)-based directed evolution platform. It was under development for the treatment of diabetic retinopathy including diabetic macular edema.
See Also:
Adverum Biotechnologies Overview
Adverum Biotechnologies (Adverum), formerly Avalanche Biotechnologies, is a clinical-stage gene therapy company. The company focuses on developing therapies to treat ocular diseases. Its product pipeline includes Ixo-vec drug candidate to treat wet age-related macular degeneration (AMD); ADVM for treatment of blue cone monochromacy (BCM); and LX2006 GTx to treat friedreich’s ataxia. Adverum also develops other drug programs for retinitis pigmentosa, and geographic atrophy. The company develops drugs in collaboration with Gensight Biologics, Lexeo Therapeutics, and Ray Therapeutics. Adverum is headquartered in Redwood City, California, the US.
The operating loss of the company was US$157.1 million in FY2022, compared to an operating loss of US$146.1 million in FY2021. The net loss of the company was US$154.5 million in FY2022, compared to a net loss of US$145.5 million in FY2021.
For a complete picture of Ixoberogene soroparvovec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
